Ben Auspitz is a Partner at F-Prime Capital, and has worked in pharmaceuticals and life-science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics.
He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Turnstone Biologics, Compass Therapeutics and Checkmate Pharmaceuticals. Previously, Ben was involved in F-Prime Capital investments in Symbiomix Therapeutics (acquired by Lupin), Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (Nasdaq: BPMC), Coherus Biosciences (Nasdaq: CHRS), REGENXBio (Nasdaq: RGNX), Dimension Therapeutics (Acquired by Ultragenyx), and Ultragenyx (Nasdaq: RARE)
He holds a B.A. from Harvard University.